U.S. markets closed

Big Biotech May Be After These Technologies

HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," Leerink analyst Geoffry Porges recently said in a Marketwatch report.

Big biotech has spent more than $100 billion in recent years on stock buybacks and the returns have been bleak. By the analyst's calculations, the companies, which include Gilead Sciences Inc., Amgen Inc., and Celgene Corp., among others, have actually produced a negative rate of return on their stock buybacks.

With 'buybacks' becoming a bad word for investors it would be prudent to expect more acquisitions and partnerships to take place in the biotech space moving forward. This makes now the best time to scout and invest in smaller biotech companies with promising technologies. We've listed a few companies we like below.

The first on our list is Endonovo Therapeutics, Inc. (ENDV). The company has an extremely promising non-invasive pain reduction treatment technology called Sofpulse that could be an answer for larger companies looking at opioid alternative pain relief solutions.

The company recently concluded a study on Sofpulse's effectiveness in treating nonalcoholic steatohepatitis (NASH). One to 2 weeks of treatment with Sofpulse appeared to counteract several of the disease signs associated with NASH-associated liver damage.

Male mice, 8 weeks old were placed on an MCD diet (methionine-choline deficient diet) for either 7 or 14 days. Feeding mice a diet deficient in methionine and choline is a commonly used mouse model to study the inflammation and hepatic ballooning associated with NASH. To determine if Endonovo's non-invasive medical device could ameliorate the manifestations of a NASH induced diet, mice were exposed to either a proprietary electroceutical therapy system or a sham system during the duration of the MCD diet.

ENDV would be a great place to start if you're looking to research potential companies that will benefit from big biotech's anticipated hunger for new technologies.

Companies to put on your radar include: Endonovo Therapeutics, Inc. (ENDV), SELLAS Life Sciences Group (SLS), Coherus Biosciences, Inc. (CHRS), Clovis Oncology, Inc. (CLVS), and Pacific Biosciences of California, Inc. (PACB).

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $15.26M Share Price: $0.041

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a distribution agreement with Magniant, LLC for the distribution of Sofpulse, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.

Alan Collier, Endonovo Chief Executive Officer, stated, "We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our Sofpulse device on a national level."

SELLAS Life Sciences Group (SLS)

Market Cap: $35.03M Share Price: $1.79

Recently, SLS a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced data from a Phase 2b clinical trial. The prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial was for the combination of nelipepimut -S (NeuVax™, NPS) +/- trastuzumab (Herceptin®) targeting HER2 low-expressing breast cancer patient cohorts. The data were presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting in Germany. CEO Dr. Angelos Stergiou MD, ScD, h.c., stated, "These data presented at ESMO today highlight the therapeutic potential of NPS for patients with early-stage triple negative breast cancer (TNBC), who currently face limited and ineffective treatment options in the adjuvant setting."

Coherus Biosciences, Inc. (CHRS)

Market Cap: $834.19M Share Price: $12.30

Coherus BioSciences, Inc., announced that the U.S. Food and Drug Administration (FDA) approved UDENYCA™ (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppressive chemotherapy. UDENYCA™ is Coherus' first drug to receive FDA or EC approval.

Clovis Oncology, Inc. (CLVS)

Market Cap: $764.84M Share Price: $14.51

CLVS incurred an adjusted loss of $1.71 per share in the third quarter of 2018, wider than the Zacks Consensus Estimate of a loss of $1.60 and the year-ago loss of $1.24 per share.

Net revenues, entirely from Clovis' only marketed drug, Rubraca, were approximately $22.8 million in the quarter, down 4.2% sequentially, due to challenges in adoption in earlier-line setting. Revenues missed the Zacks Consensus Estimate of $30.12 million. The company had recorded total revenues of $16.8 million entirely from Rubraca sales in the year-ago quarter.

Pacific Biosciences of California, Inc. (PACB)

Market Cap: $1.104B Share Price: $7.56

PACB is an example of why there's nothing like a big buyout to excite investors. Gene-sequencing giant Illumina (NASDAQ:ILMN) announced on Thursday evening that it plans to acquire PacBio for $1.2 billion.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. ENDV has paid forty-nine thousand dollars and twenty thousand restricted shares for corporate awareness services for the month of October, and continues to pay Regal to disseminate truthful and potentially material information regarding ENDV.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in ENDV can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-nine thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC